The latest price target for CytomX Therapeutics (NASDAQ:CTMX) was reported by HC Wainwright & Co. on September 13, 2024. The analyst firm set a price target for $0.00 expecting CTMX to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for CytomX Therapeutics (NASDAQ:CTMX) was provided by HC Wainwright & Co., and CytomX Therapeutics reiterated their neutral rating.

The last upgrade for CytomX Therapeutics Inc happened on May 28, 2024 when Piper Sandler raised their price target to $3.5. Piper Sandler previously had a neutral for CytomX Therapeutics Inc.

The last downgrade for CytomX Therapeutics Inc happened on November 14, 2022 when BMO Capital changed their price target from $3 to $2.6 for CytomX Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytomX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytomX Therapeutics was filed on September 13, 2024 so you should expect the next rating to be made available sometime around September 13, 2025.

While ratings are subjective and will change, the latest CytomX Therapeutics (CTMX) rating was a reiterated with a price target of $0.00 to $0.00. The current price CytomX Therapeutics (CTMX) is trading at is $1.21, which is out of the analyst’s predicted range.